Takeda closes South San Francisco R&D site in California restructuring
This article was originally published in Scrip
Executive Summary
Takeda has decided to close a US research site in South San Francisco that was specialising in the discovery of antibody therapeutics, "relocating the most essential antibody and biologics research technologies and staff" to another existing facility in San Diego.
You may also be interested in...
Takeda's Latest Investment Reflects Long-Term Shift In R&D Strategy
The Japanese pharma's new San Diego site brings together scientists from multiple locations to identify and validate therapeutic candidates across multiple modalities to enhance Takeda's global internal and external programs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.